Returning to Work After a Leave

Registrants are reminded that they are personally responsible for ensuring they are fully registered before returning to work after a leave of absence, including maternity or parental leave. This renewal should be initiated at least two weeks before the planned return to work date to allow for application processing.

To renew, the registrant must:

  • Record a minimum of 15 continuing education units (CEUs) in the online Professional Development Learning Portfolio Record;
  • Ensure they have professional liability insurance coverage in accordance with the NLPB’s Professional Liability Insurance Requirements for Registration;
  • For pharmacists only: have current membership in the Pharmacists’ Association of Newfoundland and Labrador (PANL) as required by section 21(3)(a) of the Pharmacy Act, 2012; and
  • Complete the online registration process and pay the appropriate fee.

Once all of these requirements are met, a registration certificate (“licence”) will be sent to the registrant’s personal email address on file.

Please Note: Pharmacists-in-charge are responsible for verifying that pharmacy staff members have completed these steps and are fully registered before beginning their first shift in the pharmacy, as required by section 12.(f) of the Pharmacy Regulations.

Please contact Aileen O’Keefe, Registration and Licensing Administrator at aokeefe@nlpb.ca or 709-753-5877 (extension 201) for further information.


Please Double-Check Your Contact information

Registrants are asked to ensure that the contact information they provide for themselves and the pharmacy is accurate at all times. The NLPB primarily uses email communication to send newsletters, renewal reminders, practice site assessment notifications and related paperwork, professional development audit information, calls for interest for committees, and other alerts (e.g. reports of lost or stolen TRPP pads). If the email address on file is incorrect, important information may be missed and/or disclosed to the wrong person.

If your contact information changes at any time, please be sure to update your file with your new contact information as soon as possible by logging into the Registrant Portal, linked above.

Registrants are also reminded that they are obligated to check their email on a regular basis so that important notices do not go unread.


Message from Health Canada

Health Canada is pleased to announce the release of two guidance documents:

These are being released in support of the Controlled Drugs and Substances Act (CDSA), with the aim of mitigating the risk of diversion from the downstream supply chain. The guidelines streamline, update and clarify procedures, expectations and practices related to the handling and destruction of unserviceable stock and post-consumer medications by various parties regulated under the CDSA. Key changes include:

  • The post-consumer returns guidance document sets out procedures for pharmacists involved in the collection, handling and destruction of unused or expired drug products containing a narcotic, controlled drug or targeted substance returned by an individual consumer;
  • Health Canada will no longer require the recording of the name of the drug products associated with post-consumer returns. Consequently, the requirement to separate post-consumer returned controlled substances from other post-consumer returned prescription or non-prescription medications will no longer be in effect;
  • The guidance documents require the treatment of post-consumer collection bins as if they contain controlled substances, regardless of the actual content. It is highly recommended that post-consumer returns are stored in single-use, one-way entry collection containers that are opaque, inconspicuous, tamper-evident and have a unique identifier;
  • The guidance documents replace two Circular Letters (official notices sent to targeted stakeholders) previously sent to pharmacists, practitioners, persons in charge of hospitals, and dealers licensed to destroy narcotics, controlled drugs or targeted substances; and
  • The unserviceable stock guidance document will set out procedures for practitioners, pharmacists and persons in charge of a hospital involved in the handling and destruction of these products.

The guidance documents will be considered effective in 6 months to allow the industry to accommodate these changes. Please note that an updated Section 56(1) exemption has been issued to accommodate for these changes.

Comments or questions about either of these documents should be directed to hc.compliance-conformite.sc@canada.ca.


Dose-Splitting of Lucentis, Eylea May Pose a Risk to Patient Safety

The NLPB is advising all pharmacy professionals that dose-splitting of single use Lucentis or Eylea vials may pose a risk to patient safety. Please view the following correspondence from the National Association of Pharmacy Regulatory Authorities (NAPRA) and Health Canada:

Please be reminded that the Model Standards for Pharmacy Compounding of Non-Hazardous Sterile Preparations and the Model Standards for Pharmacy Compounding of Hazardous Sterile Preparations, developed by NAPRA, have been adopted as the standard for sterile compounding in Newfoundland and Labrador. These documents are posted on the Standards, Guidelines and Policies page of the website.


New MUN School of Pharmacy podcast – The Med Thread

From opium poppies to sleeping pills, from sucking to infusing, from insomnia, anemia, auto immune diseases and beyond – we discuss the threads that led to current trends and research in medication therapy. Listen to The Med Thread monthly, as we sew a patchwork quilt with squares of history, mythology, research, sciences and technological advances. The show is produced at CHMR studios in St. John’s, Newfoundland and Labrador. For information on how to access the podcast, visit The Med Thread webpage.


Atlantic Mentorship Network-Pain & Addiction – Upcoming Continuing Education Events

The Atlantic Mentorship Network-Pain & Addiction will host the conference ‘Building a Community of Practice’ on Friday, June 15, 2018 at the Fairfield Inn & Suites St. John’s. To register for this event, visit the event website.

Topics Include:

  • Non-Pharmacological Approaches in Managing Chronic Pain
  • A Look at the Obstacles & Opportunities in Treating Pain & Addiction
  • Methadone in Palliative Care
  • Nutrition & Chronic Pain
  • Managing Pain & Addiction with Support: A Patient’s Perspective

In addition, The Atlantic Mentorship Network-Pain & Addiction will be offering The Prescribing Course-Safe Opioid Prescribing on Saturday, June 16, 2018 at the Fairfield Inn & Suites, St. John’s. The intended audience of the course is those who prescribe or dispense opioids in their practice. To learn more and register, visit the event website.


NLPB Receipts

NLPB’s registration portal maintains all receipts created by the system. If for any reason you need a copy of your paid invoice, you can log in anytime by visiting www.nlpb.ca and clicking on Registrant Login. Once logged in, click on the link called Renewal Other/Invoices and then select either view or print.


This e-newsletter contains information on a wide variety of topics intended to enhance the practice of pharmacy in the province of Newfoundland and Labrador. As it is published and circulated to all registrants on a monthly basis, it is the expectation of the NLPB that all registrants are aware of the matters contained therein.

©2018 Newfoundland & Labrador Pharmacy Board